INSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial

Bulletin Express03-06 08:02

INSILICO (03696) and TaiGen (4157.TWO) jointly announced that the out-licensed AI-driven PHD inhibitor ISM4808, targeting chronic kidney disease (CKD)-related anemia, has enrolled and dosed its first subject in a Phase I clinical trial. The study is a randomized, double-blind, placebo-controlled trial comprising single-ascending-dose and multiple-ascending-dose cohorts, designed to assess safety, tolerability, and pharmacokinetic parameters in healthy adults.

Under a licensing agreement signed in December 2025, TaiGen retains exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China. INSILICO is eligible to receive an upfront payment, development and sales-based milestone payments, and tiered royalties, with the transaction valued at a double-digit million dollars. INSILICO, listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 (stock code: 03696), focuses on integrating artificial intelligence and automation technologies in areas such as fibrosis, oncology, and immunology, extending its research to multiple industries including advanced materials and agriculture.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151276666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151276666","market":"us","top_or_hot":-1,"title":"INSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial","media":"Bulletin Express","content":"<p>INSILICO (03696) and TaiGen (4157.TWO) jointly announced that the out-licensed AI-driven PHD inhibitor ISM4808, targeting chronic kidney disease (CKD)-related anemia, has enrolled and dosed its first subject in a Phase I clinical trial. The study is a randomized, double-blind, placebo-controlled trial comprising single-ascending-dose and multiple-ascending-dose cohorts, designed to assess safety, tolerability, and pharmacokinetic parameters in healthy adults.</p>\n<p>Under a licensing agreement signed in December 2025, TaiGen retains exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China. INSILICO is eligible to receive an upfront payment, development and sales-based milestone payments, and tiered royalties, with the transaction valued at a double-digit million dollars. INSILICO, listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 (stock code: 03696), focuses on integrating artificial intelligence and automation technologies in areas such as fibrosis, oncology, and immunology, extending its research to multiple industries including advanced materials and agriculture.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-06 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INSILICO (03696) and TaiGen (4157.TWO) jointly announced that the out-licensed AI-driven PHD inhibitor ISM4808, targeting chronic kidney disease (CKD)-related anemia, has enrolled and dosed its first subject in a Phase I clinical trial. The study is a randomized, double-blind, placebo-controlled trial comprising single-ascending-dose and multiple-ascending-dose cohorts, designed to assess safety, tolerability, and pharmacokinetic parameters in healthy adults.</p>\n<p>Under a licensing agreement signed in December 2025, TaiGen retains exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China. INSILICO is eligible to receive an upfront payment, development and sales-based milestone payments, and tiered royalties, with the transaction valued at a double-digit million dollars. INSILICO, listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 (stock code: 03696), focuses on integrating artificial intelligence and automation technologies in areas such as fibrosis, oncology, and immunology, extending its research to multiple industries including advanced materials and agriculture.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1151276666","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151276666","pubTimestamp":1772755368,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"INSILICO (03696) and TaiGen (4157.TWO) jointly announced that the out-licensed AI-driven PHD inhibitor ISM4808, targeting chronic kidney disease (CKD)-related anemia, has enrolled and dosed its first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"INSILICO(03696)和TaiGen(4157.TWO)将CKD贫血候选药物ISM4808推进至I期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"INSILICO (03696) and TaiGen (4157.TWO) jointly announced that the out-licensed AI-driven PHD inhibitor ISM4808, targeting chronic kidney disease (CKD)-related anemia, has enrolled and dosed its first subject in a Phase I clinical trial. The study is a randomized, double-blind, placebo-controlled trial comprising single-ascending-dose and multiple-ascending-dose cohorts, designed to assess safety, tolerability, and pharmacokinetic parameters in healthy adults.\nUnder a licensing agreement signed in December 2025, TaiGen retains exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China. INSILICO is eligible to receive an upfront payment, development and sales-based milestone payments, and tiered royalties, with the transaction valued at a double-digit million dollars. INSILICO, listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 (stock code: 03696), focuses on integrating artificial intelligence and automation technologies in areas such as fibrosis, oncology, and immunology, extending its research to multiple industries including advanced materials and agriculture.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151276666","isCrawlerRequest":true}